A PSD-95 inhibitor and its use

By developing polypeptide inhibitors that can atypically bind PSD-95, the shortcomings of existing PSD-95 inhibitors in clinical applications have been solved, and effective prevention and treatment of neurological diseases such as stroke have been achieved.

CN118027156BActive Publication Date: 2024-11-05HUNAN ZONSEN PEPLIB BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410253107.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-07
Publication Date
2024-11-05
Estimated Expiration
2043-09-07

AI Technical Summary

Technical Problem

The existing PSD-95 inhibitors have problems such as short half-life, large doses, high cost and non-selective blockade in clinical applications, making it difficult to effectively prevent and treat neurological diseases such as stroke.

Method used

Develop a polypeptide PSD-95 inhibitor that can atypically bind to the PDZ1 and/or PDZ2 domain of PSD-95, inhibit its protein-protein interaction with nNOS, and obtain high affinity through phage display technology screening. Polypeptide sequence.

Benefits of technology

Effective inhibition of the binding of PSD-95 to nNOS is achieved, reducing the infarction area of ​​cerebral ischemia and reperfusion, improving the functional prognosis of stroke patients, and having good safety and specificity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention belongs to the technical field of biopharmaceutical polypeptides, and specifically relates to a PSD95 inhibitor and uses thereof. Furthermore, the PSD95 inhibitor described in the present invention is a polypeptide, which has a small relative molecular mass, is easy to synthesize, express and modify, and has good inhibitory efficiency on the binding of PSD95 to its receptor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a PSD-95 inhibitor and a use thereof. Background Art

[0002] N-methyl-D-aspartate receptor (NMDAR) plays an important role in the central nervous system, participating in the formation of learning and memory, the formation of synapses in the development of the central nervous system, the formation of plasticity and glutamate-mediated neurotoxicity. NMDA receptor is the main mediator of excitotoxicity (i.e., glutamate-mediated neurotoxicity), which is related to neurodegenerative diseases and acute brain injury. It can be used as a therapeutic target for certain nervous system diseases, such as cerebral infarction, neuropathic pain, epilepsy and schizophrenia.

[0003] Postsynaptic density (PSD) is a super signaling molecule complex of the excitatory postsynaptic membrane and an important substance for the transmission function of synapses. According to the weight of the molecular weight of PSD, it can be divided into four categories: PSD-95, PSD-93, synaptic associated protein 97 (SAP-97) and SAP102.

[0004] PSD-95 is the most abundant and important scaffolding protein, mainly present in mature excitatory glutamatergic synapses. Its relative molecular mass (Mr) is 95,000. It is necessary for receptor activity and stability on the postsynaptic membrane and plays an important role in synaptic plasticity. It is the most important synaptic protein that mediates and integrates synaptic information and is also a member of the guanylate-related kinase family. PSD-95 includes three PDZ domains, one SH3 domain and one guanylate kinase-like (GK) domain, which are connected by a connecting region. PSD-95 is almost entirely located in the postsynaptic density of neurons and is involved in anchoring synaptic proteins. Its direct and indirect binding partners include neuroligins, nNOS, NMDA receptors, AMPA receptors and potassium channels.

[0005] According to the different splicing of mRNA to genes, more than 10 nNOS (neuronal nitric oxide synthase) spliceosomes are known, with a molecular weight of 160.8KD. nNOS contains two structural domains, the C-terminal reduction domain and the N-terminal oxidation domain. The N-terminal has two non-overlapping binding regions: (1) PDZ region: composed of 1 to 99 amino acids, involved in the formation of active nNOS dimers; (2) β-finger structure: composed of 100-300 amino acids, containing a specific amino acid sequence -ETTF-, which can bind to the PDZ of other proteins to exert its function. nNOS can be anchored to the plasma membrane or cytosolic protein through the PDZ-PDZ domain or C-terminal PDZ reaction. PSD-95 can connect nNOS to the NMDA receptor and effectively activate nNOS through the activation of the NMDA receptor.

[0006] Stroke is characterized by the death of neurons in the ischemic area, cerebral hemorrhage area and / or trauma area. Neuronal death or damage caused by cerebral ischemia is a cascade of injury. After cerebral ischemia, tissue blood perfusion decreases, excitatory neurotransmitters increase, NMDA and AMPA receptors are activated, ion channels open, calcium ions flow in, and a large number of enzymes are activated to trigger signal cascades, resulting in multi-pathway neuronal damage. When cerebral ischemia occurs, NMDA (N-methyl-D-aspartate receptor) receptors are overactivated, and NO pathological release can be prevented by blocking the NMDA / PSD-95 / nNOS pathway. At the same time, studies have shown that blocking the coupling of NMDA / PSD-95 may produce unpredictable physiological reactions. Although NMDA receptor antagonists effectively reduce excitotoxicity by blocking glutamate-mediated ion flux, they also prevent some physiologically important processes. Its downstream PSD-95 triggers a series of ischemic injuries by interacting with various proteins. It is a key site of cerebral ischemic injury and a potential target for drug treatment. Blocking the coupling between nNOS and PSD95 is more targeted in preventing the pathological release of NO, so it is a more ideal target for preventing and treating diseases affected by neuronal damage such as ischemic stroke. Therefore, the development of PSD-95 inhibitors has great medicinal significance for various excitotoxic neurotoxicity-induced nervous system injuries, including stroke.

[0007] In addition, studies have shown that the excitatory neurotransmitter NMDA plays an important role in anxiety, epilepsy and various neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease or Huntington's disease. For example, studies have shown that excessive excitation of the central glutamatergic system can cause anxiety, and NMDA receptors (NMDARs) are responsible for the main part of glutamate excitotoxic neurotoxicity. The onset of epilepsy includes three different and continuous pathophysiological processes: initiation, maintenance and extension of paroxysmal discharges, and inhibition of paroxysmal discharges. In this process, excitatory neurotransmitters such as glutamate and aspartate play an important role. In Alzheimer's disease, PSD-95 participates in the neurotoxic mechanism leading to it through the GluR6-PSD-95-MLK3 pathway. In addition, in Huntington's disease, PSD-95 is a mediator of NMDA receptor and huntingtin mutant neurotoxicity. Therefore, the development of PSD-95 inhibitors is also of great significance for the treatment, improvement and prevention of the above diseases.

[0008] Nerinetide (NA-1, TAT-NR2B9c, sequence: YGRKKRRQRRRKLSSIESDV) is a PSD-95 inhibitor, thereby disrupting the binding of PSD-95 to NMDA receptors and neuronal nitric oxide synthase (nNOS), and reducing excitotoxicity induced by cerebral ischemia. In preclinical ischemic stroke models, it can reduce the infarct size of cerebral ischemia-reperfusion and improve its functional prognosis. Nerinetide has no serious side effects and can be used when stroke or other ischemic or hemorrhagic conditions are suspected but the diagnosis of the absence of hemorrhage has not yet been confirmed according to the standards recognized in the art. However, Nerinetide has a short half-life in vivo, patients need to take large doses every day, patient compliance is poor, clinical costs are high, and this compound may become an ineffective non-selective compound due to its low affinity with PDZ1-2 in PSD-95. To meet clinical needs, more PSD-95 inhibitors still need to be developed.

[0009] Peptides are biologically active substances that make up various cell functions in the body. They have the characteristics of small relative molecular mass, high specificity, easy absorption, easy synthesis and modification, can improve the body's immunity, and high safety. They have high application value in the clinical treatment of tumors. Phage display technology uses filamentous phages to display proteins and peptides to extract peptides or proteins with desired properties from a large number of variants.

[0010] The use of phage display technology, a high-throughput screening technology based on directed evolution, has greatly expanded the application of directed evolution technology in polypeptide modification and screening. Summary of the invention

[0011] In order to solve the deficiencies in the prior art, the present invention discloses a PSD-95 inhibitor and uses thereof, wherein the PSD-95 inhibitor can atypically bind to the PDZ1 and / or PDZ2 domains of PSD-95, thereby inhibiting the protein-protein interaction between PSD-95 and nNOS.

[0012] On the one hand, the present invention provides a polypeptide or a pharmaceutically acceptable salt thereof, wherein the polypeptide amino acid sequence comprises one of the amino acid sequences of SEQ ID NO:1 to SEQ ID NO:15 or an amino acid sequence having at least 80% sequence identity with SEQ ID NO:1 to SEQ ID NO:15 or a modified derivative of the amino acid sequence shown in SEQ ID NO:1 to SEQ ID NO:15.

[0013] In some embodiments, the polypeptide amino acid sequence comprises one of the amino acid sequences of SEQ ID NO:1 to SEQ ID NO:15, or an amino acid sequence having at least 90% sequence identity with SEQ ID NO:1 to SEQ ID NO:15, or a modified derivative of the amino acid sequence shown in SEQ ID NO:1 to SEQ ID NO:15.

[0014] In some embodiments, the polypeptide amino acid sequence comprises one of the amino acid sequences of SEQ ID NO:1 to SEQ ID NO:15, or an amino acid sequence having at least 95% sequence identity with SEQ ID NO:1 to SEQ ID NO:15, or a modified derivative of the amino acid sequence shown in SEQ ID NO:1 to SEQ ID NO:15.

[0015] In some embodiments, the polypeptide amino acid sequence is as shown in SEQ ID NO: 1 to SEQ ID NO: 15,

[0016] SAAGVVCYYWKGNIDFCHTRGGSGS(SEQ ID NO:1),

[0017] SAAGIFCEMWRGAVDFCYEWKGSGS(SEQ ID NO:2)、

[0018] SAAGCTWVTTHFDHVTWTEKVCGSGS(SEQ ID NO:3)、

[0019] SAAGCRIIETDVDTFITTLICGSGS(SEQ ID NO:4),

[0020] SAAGCKWITHFEEHVWFEMVCGSGS(SEQ ID NO:5)、

[0021] SAAGCYYITTFMEAIVTEERCGSGS(SEQ ID NO:6)、

[0022] SAAGCRYHTQFSRTVWTMWICGSGS(SEQ ID NO:7)、

[0023] SAAGCHKESIIGAQIQTIVVCGSGS(SEQ ID NO:8),

[0024] SAAGCQFETYFGEEVSTIWSCGSGS(SEQ ID NO:9),

[0025] SAAGCKQVTLFWIDVTTYYICGSGS(SEQ ID NO:10)、

[0026] SAAGCYRETTFGIRILESWHCGSGS(SEQ ID NO:11)、

[0027] SAAGMVCETMMDTWVTVCWRRGSGS(SEQ ID NO:12),

[0028] SAAGCRTWTHFIQIIITEQVCGSGS(SEQ ID NO:13)、

[0029] SAAGCQTWTTFEIFVWSELVCGSGS(SEQ ID NO:14),

[0030] SAAGCKQVTLFWIDVTTYYICGSGS (SEQ ID NO: 15).

[0031] In some embodiments, the derivative of the modified amino acid sequence is selected from one or more of the following modifications: N-terminal and / or C-terminal modification; substitution of one or more amino acid residues with one or more natural and / or non-natural amino acid residues.

[0032] In some embodiments, the modification includes amination, hydroxylation, carboxylation, carbonylation, amidation, alkylation, phosphorylation, glycosylation, cyclization, biotinylation, acetylation, esterification, fluorescent group modification, polyethylene glycol PEG modification, and immobilization modification.

[0033] The polypeptides defined herein may be in the form of a pharmaceutically acceptable salt or a prodrug of the polypeptide.

[0034] In some embodiments, the pharmaceutically acceptable salt may be selected from trifluoroacetate, acetate, hydrochloride, and phosphate.

[0035] In some embodiments, the polypeptide is obtained by using solid phase synthesis.

[0036] In some embodiments, the polypeptide is obtained by screening through phage display technology.

[0037] In another aspect, the present invention provides a polynucleotide encoding the above-mentioned polypeptide.

[0038] On the other hand, the present invention provides a pharmaceutical composition comprising the above-mentioned polypeptide or a pharmaceutically acceptable salt thereof or the above-mentioned polynucleotide and a pharmaceutically acceptable carrier, excipient and / or diluent.

[0039] In some embodiments, the polypeptide of the present application can be administered in the form of a pharmaceutical composition. The pharmaceutical composition can be manufactured by conventional mixing, dissolving, granulating, tableting, grinding, emulsifying, encapsulating, capturing or lyophilizing methods. The pharmaceutical composition can be prepared in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients or adjuvants that facilitate processing of the compound of the present application into a pharmaceutically acceptable preparation. Appropriate preparation depends on the selected route of administration.

[0040] In some embodiments, administration may be parenteral, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular.

[0041] In another aspect, the present invention provides a use of the above polypeptide or a pharmaceutically acceptable salt, polynucleotide or pharmaceutical composition thereof in the preparation of a medicament for treating, ameliorating or preventing a disease caused by abnormal PSD-95 function in an individual.

[0042] In some embodiments, the disease caused by the abnormal function of PSD-95 can be selected from cerebral infarction, neurodegenerative disease, anxiety or epilepsy, and neuropathic pain.

[0043] In some embodiments, the stroke is selected from ischemic stroke or hemorrhagic stroke.

[0044] In some embodiments, the neurodegenerative disease is selected from Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, or Huntington's disease.

[0045] As used herein, the term "phage display technology" was proposed by Smith et al. in 1985 and successfully constructed in 1989. Phage display is a selection technology that fuses polypeptides or proteins with phage coat proteins and displays them on the surface of virions. Phage display technology is a technology that inserts DNA sequences encoding exogenous polypeptides or proteins into phage genes through genetic engineering, thereby displaying polypeptides or proteins on the surface of phage capsid proteins. A large number of phages displaying different random polypeptides can constitute a phage library for screening against specific targets to explore the interaction between polypeptides and targets. In the field of biology, this technology is widely used in the study of molecular interactions such as protein-protein, protein-peptide, and protein-DNA.

[0046] The principle of phage display technology is to insert a foreign gene into the appropriate position of the phage coat protein structural gene. When the reading frame is normal and does not affect the normal function of the coat protein, the foreign gene will be expressed along with the coat protein, so that the polypeptide or protein is displayed on the phage surface in the form of a fusion protein. The displayed protein can maintain a relatively independent spatial structure and biological activity, which is conducive to the binding of the target protein. Therefore, the target protein can be used to quickly screen the phage display library. After the display library is constructed, the target protein is used as the stationary phase and incubated with the display library for a period of time, the unbound phage is washed away, and the adsorbed phage is eluted with a competitive receptor. The eluted phage infects the host bacteria for reproduction and amplification, and then the next round of elution is carried out. After 3 to 5 rounds of "adsorption-elution-amplification" (for some antibodies with weak affinity, more rounds of elution are required), a high enrichment of phages that can specifically bind to the target protein can be obtained. The significant feature of this technology is the establishment of a correspondence between genotype and phenotype.

[0047] The term "amino acid" refers to a molecule containing an amino group and a carboxyl group. Suitable amino acids include, but are not limited to, the D- and L-isomers of naturally occurring amino acids, and non-naturally occurring amino acids prepared by organic synthesis or other metabolic pathways. As used herein, the term amino acid includes, but is not limited to, α-amino acids, natural amino acids, non-natural amino acids, and amino acid analogs.

[0048] The term "naturally occurring amino acid" refers to any of the 20 L-amino acids commonly found in peptides synthesized in nature, i.e., the L-isomers of alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine ​​(Cys or C), glutamic acid (Glu or E), glutamine (Glu or Q), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V).

[0049] The meaning of the term "peptide" or "polypeptide" is well known to those skilled in the art. Generally, a peptide or polypeptide is two or more amino acids linked by an amide bond, which is formed by the amino group of one amino acid and the carboxyl group of the adjacent amino acid. The polypeptides described herein may contain naturally occurring amino acids or non-naturally occurring amino acids. They may be modified into analogs, derivatives, functional mimetics, pseudopeptides, and the like containing at least two amino acids. Unless it is specified that the N-terminus or C-terminus has a specific modification, a polypeptide comprising a specific amino acid sequence includes unmodified and modified amino and / or carboxyl termini, which is well known to those skilled in the art. A polypeptide of a specific amino acid sequence may include modified amino acids and / or additional amino acids, unless the N- and / or C-terminus contain modifications that prevent further addition of amino acids. Such modifications include, for example, acetylation of the N-terminus and / or amidation of the C-terminus.

[0050] The polypeptides of the present invention can be modified to form polypeptide derivatives. As is well known to those skilled in the art, various modifications can be made to the polypeptides. Typical modifications include, but are not limited to, N-terminal acetylation, C-terminal amidation, d-amino acid substitution, non-natural amino acid substitution, fatty acid modification, or a combination of the above modifications. The present invention includes any well-known modification of the polypeptide. For example, the polypeptide derivatives may include chemical modifications to the polypeptide, such as alkylation, acylation, carbamylation, iodination, or any other modification that produces a polypeptide derivative. The modification of the polypeptide may include modified amino acids, for example, hydroxyproline or carboxyglutamic acid, and may include amino acids connected by non-peptide bonds.

[0051] For other modifications of the polypeptide of the present invention, non-natural amino acids can be used to replace the natural amino acids in the polypeptide, including but not limited to 2-amino fatty acid (Aad), 3-amino fatty acid (βAad), β-alanine, β-aminopropionic acid (βAla), 2-aminobutyric acid (Abu), 4-aminobutyric acid, piperidine carboxylic acid (4Abu), 6-aminohexanoic acid (Acp), 2-aminoheptanoic acid (Ahe), 2-aminoisobutyric acid (Aib), 3-aminoisobutyric acid (βAib), 2-aminopimelic acid (Apm), 2,4-diaminobutyric acid (Dbu), desmosine (Des), 2,2'- Diaminopimelate (Dpm), 2,3-diaminopropionic acid (Dpr), N-ethylglycine (EtGly), N-ethylasparagine (EtAsn), hydroxylysine (Hyl), isohydroxylysine (aHyl), 3-hydroxyproline (3Hyp), 4-hydroxyproline (4Hyp), isodesmosine (Ide), isoleucine (aIle), N-methylglycine (MeGly), N-methylisoleucine (MeIle), 6-N-methyllysine (MeLys), N-methylvaline (MeVal), norvaline (Nva), norleucine (Nle) and ornithine (Orn). Of course, all modified α-amino acids can be replaced by the corresponding β-, γ- or ω-aminocarboxylic acids.

[0052] The polypeptides of the present invention can be prepared using methods well known to those skilled in the art, including well-known chemical synthesis methods. Therefore, when a polypeptide or its derivatives contain one or more non-standard amino acids, it is very likely to be prepared by chemical synthesis. In addition to using chemical synthesis methods to prepare polypeptides or their derivatives, they can also be prepared by expressing encoding nucleic acids. This is particularly applicable to the preparation of polypeptides or their derivatives containing only natural amino acids, in which case well-known methods for preparing nucleic acid encoding polypeptide sequences can be used (see Sambrook et al., Molecular Cloning: A La bora tory Manual, Third Ed., Cold Spring Harbor Laboratory, New York (2001); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999)). The polypeptide can be expressed in an organism and purified by well-known purification techniques.

[0053] The term "PDZ domain" refers to a modular protein domain of about 90 amino acids characterized by significant (e.g., at least 60%) sequence identity to the brain synaptic protein PSD-95, the Drosophila septate junction protein Discs-Large (DLG), and the epithelial tight junction protein Z01 (Z01). PDZ domains are also known as Discs-Large homology repeats ("DHRs") and GLGF repeats. PDZ domains generally show retention of a core consensus sequence (Doyle, DA, 1996, Cell 85: 1067-76). Exemplary PDZ domain-containing proteins and PDZ domain sequences are disclosed in U.S. Application No. 10 / 714,537.

[0054] Compared with the prior art, the present invention has the following beneficial effects:

[0055] The polypeptide of the present invention has a small relative molecular mass, is easy to synthesize, express and modify, and has good inhibitory efficiency on the binding of PSD95 to its receptor. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 :HPLC spectrum of the compound corresponding to the amino acid sequence of Seq ID No.1

[0057] Figure 2 :Ms spectrum of the compound corresponding to the amino acid sequence of Seq ID No.1 Specific embodiments

[0058] Synthesis Example

[0059] The polypeptide compounds and derivatives provided by the present disclosure are synthesized by a solid phase synthesis method. The synthetic carrier is Fmoc-Cys(Trt)-2-Chlotrityl Resin resin. During the synthesis process, the Fmoc-Cys(Trt)-2-Chlotrityl Resin resin is first fully swollen in N,N-dimethylformamide (DMF), and then the solid phase carrier and the activated amino acid derivative are repeatedly condensed → washed → Fmoc is removed → washed → the next round of amino acid condensation is performed to achieve the desired length of the polypeptide chain to be synthesized, and finally a mixed solution of trifluoroacetic acid: water: triisopropylsilane: anisyl thioether (90:2.5:2.5:5:, v:v:v:v) is reacted with the resin to cleave the polypeptide from the solid phase carrier, and then a solid crude product of a linear precursor is obtained after precipitation by frozen methyl tert-butyl ether. The crude linear precursor after cleavage is subjected to disulfide bond oxidation in an alkaline solution to obtain a crude target polypeptide. The crude polypeptide was purified and separated by C-18 reverse phase preparative chromatography in 0.1% trifluoroacetic acid acetonitrile / water system to obtain pure polypeptide and its derivatives.

[0060] Experimental reagents

[0061]

[0062]

[0063] The following only lists the synthesis method of Seq ID No. 1 as an example, and the other sequences can refer to the method of Example 1. The specific synthesized amino acid sequence is shown in Table 1.

[0064] Example 1: Synthesis of compounds corresponding to the amino acid sequence of Seq ID No.1

[0065] Step 1: Coupling of the first amino acid Fmoc-Cys(Trt)-OH

[0066] 84 mg (0.1 mmol) of 2-Chlorotrityl chloride resin was fully swollen in DCM for 1 h. Fmoc-Cys(Trt)-OH (0.08 mmol) and diisopropylethylamine (DIEA, 0.32 mmol) were weighed and dissolved in 5 ml of DCM and added to the resin to react at room temperature for 2 h. After the reaction was completed, a blocking solution (10 ml) of DCM: methanol: DIEA (85:10:5, v:v:v) was added at room temperature for 10 min for blocking. The blocked resin was washed 5 times with DCM and 5 times with DMF.

[0067] Step 2: Synthesis of linear precursor peptide chain

[0068] SAAGVVCYYWKGNIDFCHTRGGSGS

[0069] The resin obtained in step 1 was fully swollen in DMF for 1 h, and then the linear precursor sequence was synthesized from the second position of the carboxyl terminal to the amino terminal. Each coupling cycle was performed as follows:

[0070] · Fmoc-deprotection was performed twice with 20% piperidine / DMF (20% v / v, 10 mL), each time for 8 min.

[0071] • Rinse the resin 6-8 times with DMF until neutral pH.

[0072] Dissolve 0.5 mmol Fmoc-AA, 0.5 mmol 6-chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) and 1 mmol 4-methylmorpholine (NMM) in DMF, add to the resin and react at room temperature for 1 h.

[0073] • Rinse the resin 4-6 times with DMF before coupling the next amino acid.

[0074] After the linear peptide synthesis, the resin was washed 5 times with DMF and 5 times with DCM. The resin was dried in vacuo.

[0075] Step 3: Cleavage of the linear precursor peptide chain

[0076] Freshly prepared cutting cocktail (10 mL) trifluoroacetic acid: water: triisopropylsilane: thioanisole (90:2.5:2.5:5, v:v:v:v) was added to the resin obtained in step 2 and shaken for 2 hours at room temperature. After the reaction, the reaction solution was filtered, and the resin was washed with trifluoroacetic acid, combined with the reaction solution, and precipitated with 4 volumes of cold MTBE to obtain a crude product. The crude product was washed with MTBE 3 times and dried in a vacuum.

[0077] Step 4: Intramolecular disulfide bond formation

[0078] Add DMSO to the crude product obtained in step 3 to fully dissolve (the volume of DMSO is 20% of the total volume of the reaction system), then slowly add the dissolved polypeptide solution dropwise to 50% acetonitrile aqueous solution to a final concentration of 1 mg / ml, and shake at room temperature for 16 hours. LC-MS monitors the reaction results, and purification is directly performed after the reaction is completed.

[0079] Step 5: Peptide purification

[0080] The crude polypeptide was dissolved in 20% acetonitrile aqueous solution, filtered through a 0.45um membrane, and separated using a reversed-phase high-performance liquid chromatography system, with buffers A (0.1% trifluoroacetic acid, aqueous solution) and B (0.1% trifluoroacetic acid, acetonitrile). The chromatographic column was a BR-C18 (Saifen) reversed-phase column, and during the purification process, the chromatograph detection wavelength was set at 230nm, the flow rate was 15mL / min, and the gradient was 20-50% acetonitrile in 40min. The product-related fractions were collected, and after HPLC identification of the purity, the fractions >95% were combined and freeze-dried to obtain the pure polypeptide.

[0081] Step 6: Detection and characterization methods

[0082] The purity and molecular weight of the peptide obtained in step 5 were determined by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry. The obtained amino acid sequence is shown in Table 1.

[0083] Table 1 Amino acid sequences used in the examples

[0084] serial number sequence 1 SAAGVVCYYWKGNIDFCHTRGGSGS 2 SAAGIFCEMWRGAVDFCYEWKGSGS 3 SAAGCTWVTHFDHVTWTEKVCGSGS 4 SAAGCRIIETDVDTFITTLICGSGS 5 SAAGCKWITHFEEHVWFEMVCGSGS 6 SAAGCYYITTFMEAIVTEERCGSGS 7 SAAGCRYHTQFSRTVWTMWICGSGS 8 SAAGCHKESIIGAQIQTIVVCGSGS 9 SAAGCQFETYFGEEVSTIWSCGSGS 10 SAAGCKQVTLFWIDVTTYYICGSGS 11 SAAGCYRETTFGIRILESWHCGSGS 12 SAAGMVCETMMDTWVTVCWRRGSGS 13 SAAGCRTWTHFIQIIITEQVCGSGS 14 SAAGCQTWTTFEIFVWSELVCGSGS 15 SAAGCKQVTLFWIDVTTYYICGSGS

[0085] Biological Test Examples

[0086] Test Example 1: ELISA test of peptide samples inhibiting the binding of Tat-NR2B9c-B and cMyc-PSD95 alpha 1-392

[0087] 1) Main experimental materials

[0088]

[0089] 2) Experimental steps:

[0090] The ELISA (enzyme-linked immunosorbent assay) method was used to test the inhibitory effect of peptide samples on Tat-NR2B9c-B binding to cMyc-PSD95 alpha 1-392. cMyc-PSD95 alpha 1-392 was coated on a 384-well plate (greiner 781097) at 0.37μg / ml, 25ul / well. After blocking the ELSIA plate coated with cMyc-PSD95 alpha 1-392, the peptide samples were diluted to 0-10μM (from 10μM down 3-fold gradient dilution for a total of 8 concentrations). The workstation was used to transfer 12.5μl / well of the peptide sample to the 384-well plate, and the bubbles were removed by instant centrifugation. Then, an 8-well pipette (10-100ul) was used to transfer 12.5μl / well of 12nM Tat-NR2B9c-B, and the bubbles were removed by instant centrifugation and incubated at 37℃ for 1h. Discard the liquid in the wells, add 80μl 1×TBST washing solution with pH=7.4 and wash the plate 3-5 times, 3-5 minutes each time. Drain the test plate and add 25μL / well of 1:10000 diluted Streptavidin HRP, centrifuge to remove bubbles and incubate in a 37℃ incubator for 1h. Wash the plate again and drain the test plate, add 25μl TMB colorimetric solution to each well, and continue to incubate in the incubator at 37℃ for 30min. Finally, add 25μl stop solution (1MHCL) to each well to terminate the reaction. Use the microplate reader Cytation5 to read the absorbance at 450nm.

[0091] 3) Experimental results

[0092] The ELISA method was used to test the inhibitory effect of the polypeptide of the present invention on the binding of Tat-NR2B9c-B and PSD95-related proteins. The measured results were shown in Table 2 through the obtained IC50 values; the results showed that the polypeptide of the present invention has good inhibitory activity on the binding of cMyc-PSD95alpha 1-392 and Tat-NR2B9C-B.

[0093] Table 2: IC50 values ​​of peptide binding to cMyc-PSD95 alpha 1-392 and Tat-NR2B9C-B by ELISA

[0094] serial number IC50(μM) serial number IC50(μM) 1 17.2 9 53.02 2 77.07 10 4.66 3 20.95 11 20.56 4 6.1 12 20.2 5 37.72 13 14.23 6 39.65 14 33.47 7 1.802 15 8.573 8 26.71

[0095] Test Example 2: FRET test peptide sample inhibits the binding of cMyc-PSD95 alpha 1-392 and Tat-NR2B9C-B

[0096] 1) Main experimental materials

[0097]

[0098] 2) Experimental steps:

[0099] The FRET (fluorescence resonance energy transfer) method was used to test the inhibitory effect of peptide samples on the binding of cMyc-PSD95 alpha 1-392 to Tat-NR2B9C-B. The peptide samples were diluted to 0-10μM (from 10μM down 3-fold gradient dilution for a total of 8 concentrations). Use an 8-well pipette (1-10ul) to transfer 4μl / well of 4nM cMyc-PSD95 alpha 1-392 to a 384-well white plate (Thermo 264706) and centrifuge to remove bubbles. Use a workstation to transfer 4μl / well of the peptide sample to a 384-well plate and centrifuge to remove bubbles. Use an 8-well pipette again to transfer 4μl / well of 20nM Tat-NR2B9c-B to a 384-well white plate and centrifuge to remove bubbles. Mix the prepared 0.02μg / ml EU-steptavidin with 1ug / ml Mouse Anti-C-MYC IgG SureLight APC in a 1:1 ratio. Use an 8-well pipette to transfer 8μl / well of EU-APC premix to a 384-well white plate, and centrifuge to remove bubbles. Incubate at room temperature in the dark for 2 hours, and use a microplate reader cytation5 to read the emission fluorescence values ​​at 320nM excitation 620nm and 665nm.

[0100] 3) Experimental results

[0101] The FRET method was used to test the inhibitory effect of the polypeptide of the present invention on the binding of Tat-NR2B9c-B and PSD95-related proteins. The measured results were shown in Table 3 through the obtained IC50 values; the results showed that the polypeptide of the present invention has good inhibitory activity on the binding of cMyc-PSD95alpha 1-392 and Tat-NR2B9C-B.

[0102] Table 3: IC50 values ​​of FRET test peptides binding to cMyc-PSD95 alpha 1-392 and Tat-NR2B9C-B

[0103] serial number IC50(μM) serial number IC50(μM) 2 22.59 9 3.65 3 1.91 10 1.12 4 1.37 11 7.99 5 3.76 12 14.49 6 10.95 13 1.73 7 2.02 14 3.12 8 30.02 15 8.573

[0104] Test Example 3: ELISA test of peptide samples inhibiting the binding of biotin-nNOS1-299 and cMyc-PSD95 alpha 1-392 1) Main experimental materials

[0105]

[0106] 2) Experimental steps:

[0107] The ELISA (enzyme-linked immunosorbent assay) method was used to test the inhibitory effect of peptide samples on biotin-nNOS1-299 binding to cMyc-PSD95 alpha 1-392. cMyc-PSD95 alpha 1-392 was coated on a 384-well plate (greiner 781097) at 10μg / ml, 25ul / well. After blocking the ELSIA plate coated with cMyc-PSD95 alpha 1-392, the peptide samples were diluted to 0-10μM (from 10μM down 3-fold gradient dilution, a total of 8 concentrations). Use the workstation to transfer 12.5μl / well of the peptide sample to a 384-well plate, centrifuge to remove bubbles. Then use an 8-well pipette (10-100ul) to transfer 12.5μl / well of 10μg / ml 743biotin-nNOS1-299, centrifuge to remove bubbles, and incubate at 37℃ for 1h. Discard the liquid in the well, add 80μl of 1×TBST washing solution with pH=7.4, wash the plate 3-5 times, 3-5min each time. Add 25μL / well of Streptavidin HRP diluted 1:10000 to the test plate, centrifuge to remove bubbles, and incubate in a 37℃ incubator for 1h. Wash the plate again, add 25μl of TMB colorimetric solution to each well, and continue to incubate in the incubator at 37℃ for 30min. Finally, add 25μl of stop solution (1M HCL) to each well to terminate the reaction. The absorbance at 450 nm was read using a Cytation5 microplate reader.

[0108] 3) Experimental results

[0109] The ELISA method was used to test the inhibitory effect of the polypeptide of the present invention on the binding of biotin-nNOS1-299 and PSD95-related proteins. The measured results were shown in Table 4 through the obtained IC50 values; the results showed that the polypeptide of the present invention has good inhibitory activity on the binding of biotin-nNOS 1-299 and PSD95-related proteins.

[0110] Table 4: IC50 values ​​of ELISA test peptides inhibiting the binding of biotin-nNOS1-299 to cMyc-PSD95 alpha 1-392 related proteins

[0111] serial number IC50(μM) serial number IC50(μM) 1 5.61 9 1.06 2 0.41 10 0.05 3 0.39 11 0.54 4 0.81 12 0.55 5 0.30 13 0.06 6 0.91 14 0.22 7 0.10 15 0.02 8 0.49

[0112] The present invention provides a polypeptide of a PSD-95 inhibitor and its application. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

Claims

1. A polypeptide or a pharmaceutically acceptable salt thereof, It is characterized in that The polypeptide amino acid sequence is shown in SEQ ID NO:

4.

2. The polypeptide according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The polypeptide is obtained by screening through phage display technology. A polynucleotide encoding the polypeptide according to claim 1 or 2.

4. A pharmaceutical composition comprising the polypeptide according to claim 1 or 2 or a pharmaceutically acceptable salt thereof or the polynucleotide according to claim 3 and a pharmaceutically acceptable carrier.

5. Use of the polypeptide or pharmaceutically acceptable salt thereof according to claim 1 or 2, the polynucleotide according to claim 3, or the pharmaceutical composition according to claim 4 in the preparation of a medicament for treating, ameliorating or preventing a disease caused by PSD-95 dysfunction in an individual; wherein the disease caused by PSD-95 dysfunction is selected from at least one of stroke, amyotrophic lateral sclerosis, and neuropathic pain.